REDWOOD CITY, Calif., Feb. 17 /PRNewswire/ -- Codexis, Inc. today announced two separate collaborations in pharmaceutical manufacturing with Dishman Pharmaceuticals and Chemicals and AMPAC Fine Chemicals LLC (AFC), a subsidiary of American Pacific Corporation. These agreements expand the application of Codexis technology to a broadened pipeline of branded innovator pharmaceutical products.
Under the new agreements, Codexis will apply its proprietary biocatalyst technology to selected therapeutic products in the collaborators' portfolios to reduce cost, increase manufacturing efficiency and lessen environmental impact. Codexis technology is used at innovator pharmaceutical companies to enable cost-effective manufacturing processes at commercial scale.
Dishman, headquartered in Ahmedabad, India, is a global outsourcing partner manufacturing active pharmaceutical ingredients (APIs) and intermediates for the pharmaceutical industry. Dishman operates 12 API and intermediate production facilities in India, China, Switzerland and the UK manufacturing products for leading global innovator drug companies worldwide. Under the terms of the agreement, Codexis and Dishman will work exclusively to supply intermediates and active ingredients manufactured using Codexis technology to a select group of innovators; Dishman will be Codexis' preferred CMO partner for new opportunities at other innovators.
AFC, headquartered in Rancho Cordova, CA, is a custom manufacturer of pharmaceutical fine chemicals. The company specializes in technology using high energetic chemistry and other specific technologies which are advantageous for certain classes of products.
"These new partnerships bring Codexis technology to an expanded portfolio of innovator pharmaceutical products. They will be important as we continue to serve our pharmaceutical customers worldwide," said Alan Shaw, Ph.D., President and Chief Executive Officer.
Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale. Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals.
Contact: Lyn Christenson, email@example.com, 650-421-8144 or Saskia Sidenfaden, firstname.lastname@example.org, 212-827-3771.
SOURCE Codexis, Inc.